Search

Displaying results 5401 - 5410 of 5758 in total
  1. Drug

    Ancestim

    go.drugbank.com/drugs/DB09103
    ApprovedWithdrawn

    It is a 166 amino acid protein produced by E. coli with an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis, except for the addition of an N-terminal

  2. Drug

    Brexpiprazole

    go.drugbank.com/drugs/DB09128
    ApprovedInvestigational

    Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM). It has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. A...

    Synonyms: Lu-AF41156Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  3. Drug

    Technetium Tc-99m tetrofosmin

    go.drugbank.com/drugs/DB09160
    Approved

    Technetium Tc-99m tetrofosmin is a drug used in nuclear myocardial perfusion imaging. The radioisotope, technetium-99m, is chelated by two 1,2-bis[di-(2-ethoxyethyl)phosphino]ethane ligands which belong to the group of diphosphines and w...

    Categories: P-glycoprotein substrates
  4. Drug

    Rivoglitazone

    go.drugbank.com/drugs/DB09200
    Investigational

    Rivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes. It is being developed by Daiichi Sankyo Co.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 Inhibitors
  5. Drug

    Dexibuprofen

    go.drugbank.com/drugs/DB09213
    ApprovedWithdrawn

    Dexibuprofen, S(+)-ibuprofen, is a non-steroidal anti-inflammatory drug (NSAID). It is a pharmacologically effective enantiomer of racemic ibuprofen that differs in physicochemical properties. It is proposed to be more pharmacologically ...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 SubstratesSynonyms: (+)-(S)-p-isobutylhydratropic acid
  6. Drug

    Azelnidipine

    go.drugbank.com/drugs/DB09230
    Investigational

    Azelnidipine is a dihydropyridine calcium channel blocker. It is marketed by Daiichi-Sankyo pharmaceuticals, Inc. in Japan. It has a gradual onset of action and produces a long-lasting decrease in blood pressure, with only a small increa...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  7. Drug

    Lacidipine

    go.drugbank.com/drugs/DB09236
    Approved

    Lacidipine is a lipophilic dihydropyridine calcium antagonist with an intrinsically slow onset of activity. Due to its long duration of action, lacidipine does not lead to reflex tachycardia . It displays specificity in the vascular smoo...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  8. Drug

    Niguldipine

    go.drugbank.com/drugs/DB09239
    Experimental

    Niguldipine is a calcium channel blocker drug (CCB) with a1-adrenergic antagonist properties.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  9. Drug

    Niludipine

    go.drugbank.com/drugs/DB09240
    Experimental

    Niludipine is a calcium channel blocker.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  10. Drug

    Lumacaftor

    go.drugbank.com/drugs/DB09280
    ApprovedInvestigational

    Lumacaftor is a drug used in combination with DB08820 as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused ...

    Categories: Cytochrome P-450 CYP2B6 Inducers, P-glycoprotein inducers